Shreveport's The Bridge hosts open house on dementia care
SHREVEPORT, La. (KTAL/KMSS) — Starting on Tuesday, June 3, The Bridge Alzheimer's & Dementia Resource Center will host open house tours every other Tuesday from 1:30 p.m. to 3:30 p.m.
'The Bridge' offers support to caregivers
The Bridge is the region's first dementia-centered adult day program. During the Tuesday tours, visitors will be able to meet the team, explore what services are available, and learn more about The Bridge's programs.
Executive Director of The Bridge Alzheimer's & Dementia Resource Center Toni Goodin said, 'We want people to know that they're not alone. These tours are a simple way for anyone—whether a caregiver, family member, or healthcare provider—to come see what we offer and ask questions in a relaxed, welcoming setting.
More Health & Wellness
The Bridge is, 'a 501(c)(3) nonprofit organization dedicated to providing education, resources, and support for individuals living with Alzheimer's disease and related dementias, as well as their caregivers.'
The Tuesday tours do not require a reservation; guests can stop by during the tour hours.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Chicago Fire reveal plans for new stadium in Chicago's South Loop
The Chicago Fire have announced plans to build a brand-new stadium. This will be a soccer-specific stadium, in the long-vacant plot of land in the South Sloop, known as "The 78." The team says it will be privately funded. It is estimated that it will house 22,000 fans. Construction will begin as soon as this fall and be finished in time for the 2028 Major League Soccer season.
Medscape
an hour ago
- Medscape
GLP-1 Less Frequent Dosing May Maintain Weight Loss
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence supporting its effectiveness is lacking. Researchers used a combination of real-world case reports and mathematical modeling to examine the efficacy of a less frequent dosing of GLP-1 RAs for weight maintenance. They analyzed the data of two patients who used GLP-1 RAs at less frequent dosing schedules than recommended; patient 1 with obesity and prediabetes self-administered 7.5 mg tirzepatide every 10-14 days, whereas patient 2 with uncontrolled type 2 diabetes managed intermittent dosing of 15 mg tirzepatide due to supply shortages. A mathematical pharmacokinetic-pharmacodynamic model was used to simulate long-term changes in body weight of virtual patients administered semaglutide and tirzepatide at various dosing intervals. Simulations modeled semaglutide (2.4 mg) or tirzepatide (5 mg, 10 mg, or 15 mg) as a once-weekly dosing for 120 weeks, after which the 7-day dosing interval was increased to 10, 14, or 28 days or retained. TAKEAWAY: Patient 1 achieved an additional 13.7% body weight loss over 7 months and maintained it thereafter. Patient 2 lost 30% of her body weight and safely stopped insulin; even with intermittent dosing of tirzepatide, she retained a 22.8% body weight loss from baseline. Mathematical modeling predicted that switching from one dose per week to one dose every 2 weeks maintained 72% and 78% of the body weight loss achieved with 2.4 mg semaglutide and 15 mg tirzepatide, respectively. Even monthly dosing may have preserved half of the body weight loss achieved with weekly dosing, demonstrating that the reduction in efficacy was not proportional to the reduction in dosing frequency. IN PRACTICE: 'Future studies are needed to identify patient factors that predict a more favorable response to less frequent dosing of incretin mimetics and to examine the long-term clinical outcomes achieved through this approach compared with other off-ramping options (eg, switching to alternative AOMs [anti-obesity medications]),' the authors wrote. SOURCE: This study was led by Calvin C. Wu, Tono Health, Brooklyn, New York. It was published online in Obesity . LIMITATIONS: No limitations were provided for this study. DISCLOSURES: Two authors reported receiving funding from the National Science Foundation. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. Credit Lead image: KKfotostock/Dreamstime Medscape Medical News © 2025 WebMD, LLC Cite this: Edited by Javed Choudhury. GLP-1 Less Frequent Dosing May Maintain Weight Loss - Medscape - June 03, 2025.
Washington Post
an hour ago
- Washington Post
Belmont Stakes odds, post positions, favorites and analysis
The 157th Belmont Stakes is Saturday night at Saratoga Race Course, the second consecutive year the race will be staged in Upstate New York because of renovations at Belmont Park, the usual host. This year's race covers 1¼ miles, shorter than Belmont's traditional 1½, and offers a $2 million purse. The field has a compelling mix of contenders, including Kentucky Derby winner Sovereignty, who returns after skipping the Preakness Stakes, and Preakness victor Journalism, each aiming to secure two legs of the Triple Crown. Other notable entrants are Hill Road, fresh off a win in the Peter Pan Stakes, and international competitor Heart of Honor, who seeks to make his mark on U.S. soil after mostly racing in Dubai.
